key: cord-0707805-973bm42n
authors: Van Elslande, Jan; Oyaert, Matthijs; Lorent, Natalie; Weygaerde, Yannick Vande; Van Pottelbergh, Gijs; Godderis, Lode; Van Ranst, Marc; André, Emmanuel; Padalko, Elizaveta; Lagrou, Katrien; Vandendriessche, Stien; Vermeersch, Pieter
title: Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
date: 2022-02-12
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2022.115659
sha: dddaf0c927fa8e704441857aa7bbedaa01015426
doc_id: 707805
cord_uid: 973bm42n

We retrospectively compared the long-term evolution of IgG anti-spike (S) and anti-nucleocapsid (N) levels (Abbott immunoassays) in 116 non-severe and 115 severe SARS-CoV-2 infected patients from 2 university hospitals up to 365 days post positive RT-PCR. IgG anti-S and anti-N antibody levels decayed exponentially up to 365 days after a peak 0-59 days after positive RT-PCR. Peak antibody level/cut-off ratio 0-59 days after positive RT-PCR was more than 70 for anti-S compared to less than 6 for anti-N (p<0.01). Anti-S and anti-N were significantly higher in severe compared to non-severe patients up to 180-239 days and 300-365 days, respectively (p<0.05). Despite similar half-lives, the estimated time to 50% seronegativity was more than 2 years for anti-S compared to less than 1 year for anti-N in non-severe and severe COVID-19 patients, due to the significantly higher peak antibody level/cut-off ratio for anti-S compared to anti-N.

Most individuals produce specific antibodies directed against the spike (S) and the nucleocapsid (N) protein after an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with seroconversion rates of 85-100% in the first weeks after infection [1] [2] [3] [4] [5] . Anti-N IgG antibodies become detectable several days earlier than anti-S antibodies, both with automated immunoassays and lateral flow immunoassays [6, 7] . Seroconversion for IgG occurs approximately 2 weeks after onset of symptoms and, similar to SARS-CoV-1, around the same time as IgM and IgA [8] [9] [10] . Despite some early reports describing rapid seroreversion within 3 months [11, 12] , recent studies on long-term antibody kinetics demonstrated that many infected individuals still show detectable anti-S antibodies for up to [12] [13] [14] months after infection [13] [14] [15] [16] [17] . The half-life and time to seronegativity of anti-SARS-CoV-2 antibodies depends on antibody class and the antigenic target, with IgG remaining positive a longer period than IgM and IgA [2, 4, 9, 18] and anti-S antibodies persisting for a longer period than anti-N [4, 15, [19] [20] [21] [22] [23] [24] . IgG levels seem to peak around 2-8 weeks after infection, followed by an initial fast waning and subsequent slowing of antibody decay after 4-6 months [16, 23, 25, 26] . Note that the observed antibody kinetics are assay-dependent, as several studies have shown longer seropositivity and even increases in signal over time using the competitive total Ig Roche Elecsys anti-N and anti-S immunoassays, while antibody levels typically decline using non-competitive IgG immunoassays [19, [27] [28] [29] [30] . The signal of competitive total Ig immunoassays is impacted by antibody avidity and relative abundance of the different immunoglobulin classes, impacting longterm kinetics [19, [27] [28] [29] [30] .

The presence and amount of IgG anti-SARS-CoV-2 antibodies, particularly anti-S, has been shown to correlate with neutralizing antibody titers [31, 32] and protection from (re)infection [22, [33] [34] [35] . Individuals who had a more severe COVID-19 episode seem to produce higher peak antibody levels and remain seropositive for longer, which might influence protection from reinfection [16, 24, 32, [36] [37] [38] . Several studies have estimated the protection against repeat infection around 80-95% for at least six to ten months in seropositive individuals after primary SARS-CoV-2 infection [39] [40] [41] [42] . If reinfection does occur, it's severity is usually milder compared to a primary infection [43] . The available SARS-CoV-2 vaccines induce a strong initial humoral immune response [44] , with subsequent waning of antibody levels and protective efficacy in the months following vaccination [45] [46] [47] . Vaccinated individuals with a history of prior COVID-19 ("hybrid immunity") show higher antibody levels and longer lasting protection following vaccination, compared to vaccinated immune naive individuals [44, 48] . Individuals with hybrid immunity are better protected against highly immune-evading variants such as the recently reported Omicron variant [49] .

Characterization of the long-term humoral immune response after natural infection is of importance to understand and develop strategies against the ongoing COVID-19 pandemic [15, 16] .

In this study, we report the long-term kinetics of anti-S and anti-N levels in nonsevere and severe COVID-19 patients up to 12 months after first positive reverse transcriptase polymerase chain reaction (RT-PCR), and estimate half-life and time to seronegativity of IgG anti-S and IgG anti-N.

This retrospective study was performed at the University Hospitals Leuven and Ghent University Hospital (Belgium) after approval by the local ethics committees from both hospitals (S63897 and BC07662, respectively).

The long-term kinetics of anti-S and anti-N were determined in 882 residual samples from 231 adult patients who were positive for SARS-CoV-2 with RT-PCR on nasopharyngeal swabs between March 9 th and June 12 th 2020, before the introduction of SARS-CoV-2 vaccines. The circulating strains at the time precede the emergence of the variants of concern and thus correspond to "wild type" strains. 

Patients were classified after a review of the patient records as described previously [50] : 1) mild (n=41): mild clinical symptoms without manifestation of pneumonia on imaging; 2) moderate (n=75): fever, respiratory symptoms, and with radiological findings of pneumonia; 3) severe (n=68): meeting any one of the following criteria: respiratory distress, hypoxia (SpO 2 ≤93%), or abnormal blood gas analysis: (P a O 2 <60mmHg, P a CO 2 >50 mmHg); 4) critical (n=47): meeting any one of the following criteria: respiratory failure requiring mechanical ventilation, shock, organ failure that requires ICU care or death of the patient due to COVID-19. Mild and moderate patients were considered together as "non-severe patients" and severe and critical patients as "severe patients".

The inclusion criterion was at least 2 available residual samples (range 2-12 samples/patient) including at least one sample collected 30 days or later after the first positive RT-PCR. This criterion ensured that a longitudinal evolution of antibody levels could be determined for each patient. In Figure 3 we included the results of a previously published study in 118 healthcare workers (HCW) with an asymptomatic or mild SARS-CoV-2 infection (Ethics committee aproval S64152) [21] and a group of 13 asymptomatic individuals (39 samples) who tested positive with RT-PCR and for whom we had at least 1 sample 60 days after positive RT-PCR (Ethics committee approval S63897 and BC07662).

Samples were included regardless whether or not a patient became seronegative.

Severely immunocompromised patients (hematological cancer, recent organ transplantation) and patients receiving the B-cell suppressing agents rituximab or azathioprine were excluded.

Antibodies were measured on Abbott Architect (Abbott, Lake Forest Illinois) with the chemiluminiscence SARS-CoV-2 IgG (anti-N) and IgG II Quant (anti-S) assays using the manufacturer's cut-offs for positivity of 1.4 S/CO and 50 AU/mL, respectively.

The specificity of the IgG anti-S assay was determined in 110 left-over samples collected before January 2020 that were previously used to evaluate the specificity of the Abbott IgG anti-N assay [36] . Three of the original 113 samples were excluded because of insufficient volume. The tested samples were serum or lithium heparin plasma, both appropriate sample types according to the manufacturer's instructions.

Samples above the extended measuring range of 80.000 AU/mL for anti-S were further diluted 1:2 using Abbott multi-assay manual diluent. The units of the quantitative Abbott anti-S assay (AU/mL) which uses a 6-point calibration curve can converted to WHO units (BAU/mL) by multypling with a factor of 0.142 according to the manufacturer. This is not possible for the semi-quantitative Abbott anti-N assay (S/CO) which only uses a 2-point calibration curve.

Due to supply limitations 4 different PCR platforms were used in the University Hospitals Leuven: Hologic Panther Fusion system (Hologic, Marlborough, Massachusetts), Hologic Panther Aptima SARS-CoV-2 assay, Xpert Xpress SARSCoV-2 (Cepheid, Sunnyville, California), and an in-house method complying with the WHO guidelines [51] .

In Ghent University Hospital, only one PCR platform was used: an in-house PCR for E-gene (FAM) using primers described by Corman et a [51] . Nucleic acid extraction was performed automatically using NucliSENS Easymag (Biomérieux, Marcy l'Etoile, France). Reverse transcription and amplification was performed using the Qiagen One

Step RT-PCR Kit (Qiagen, Hilden, Germany) with the Dia ControlRNA (Diagenode, Liège, Belgium) (Cy5) as internal control. PCR was performed using a CFX96 real-time cycler and results were analysed with CFX software (Bio-Rad, Hercules, California). Positivity was determined based on a cycle threshold (Ct) value below 42, a threshold determined after internal validation.

The percentage of patients who seroconverted and the percentage of patients who were seropositive in a given time window were compared using Fisher's exact test, and 95% confidence intervals were calculated using the modified Wald method method with Graphpad QuickCalcs (www.graphpad.com/quickcalcs/). Antibody levels and estimated median time to seronegativity were compared using a non- 

The patient characteristics are described in Table 1 . The median age did not differ between non-severe and severe patients, but the proportion of men was significantly higher in severe than in non-severe patients (p<0.01, Table 1 Table   2 ). In contrast, anti-N seropositivity decreased significantly after day 59 (see Table   2 ), with a higher fraction of severe patients testing positive in every 60 day window compared to non-severe patients ( Table 2) Table 2 ). Figure 1 shows the correlation of the quantitative results of anti-S and anti-N of all the included samples in each 60-day time window.

The median antibody levels for anti-S and anti-N were the highest in the 0-59 day window in both severe and non-severe patients, followed by an exponential decline ( Figure 2 and 3, Table 2 ). In the 0-59 day window after positive RT-PCR, the median peak antibody level/cut-off ratio was more than 70 for anti-S compared to less than 6 for anti-N in severe as well as in non-severe patients (p<0.01 each). After this peak, an waning of antibody levels was observed up to 365 days after positive RT-PCR ( Figure 3 ). Antibody levels were significantly higher in severe compared to nonsevere patients in each 60 day time window up to 300-365 days for anti-N and up to 180-239 days for anti-S (Supplemental Figure 1) . Anti-S antibody levels remained higher in severe compared to non-severe COVID-19 patients 240-299 and 300-365 days after positive RT-PCR, but the difference was no longer statistically significant (p=0.06 and p=0.13, respectively).

Multiple regression revealed that days post positive RT-PCR and severity were significant predictors of the antibody levels for both anti-S and anti-N. In addition, age but not gender was a significant predictor for anti-S levels, while the opposite was true for anti-N levels. A multiple regression analysis with only days post positive RT-PCR and gender or age (<62 or ≥62 years old, the median age of the severe patient cohort) as covariates confirmed the above-mentioned associations (Supplemental Figure 2) . Results of these multiple regression analyses should, however, be interpreted with caution as the covariates are not independent (e.g. men have a higher risk of severe COVID-19 (see Table 1 )).

The computed mean half-life between day 60 and 365 after positive PCR (based on a one-phase exponential decay model) for anti-S was 141. 6 

We studied the dynamics of SARS-CoV-2 IgG anti-S and anti-N antibody levels in non-severe and severe COVID-19 patients up to 365 days after first positive RT-PCR. Significantly more non-severe patients seroconverted for anti-S than for anti-N and anti-N seropositivity declined more rapidly compared to anti-S. This difference in generation and persistence of anti-N versus anti-S antibodies is in line with other studies across different populations and analytical platforms [4, 15, [19] [20] [21] [22] [23] [24] . The fact that most individuals remained seropositive for anti-S up to a year after primary infection confirms other studies with a similar follow-up duration [13] [14] [15] [16] [17] 38] . IgG anti-S and anti-N levels, as well as anti-N seroconversion rate, were significantly higher in patients who had severe COVID-19 compared to non-severe patients, in line with previous studies [16, 21, 24, 32, [36] [37] [38] .

In the seropositive patients of our study, anti-S and anti-N antibody levels decreased exponentially following an initial peak 0-59 days after positive PCR without reaching an apparent plateau at the end of follow-up. A "one phase" exponential decay during the first months after infection has been described by several reports [4, 22] although some authors have suggested that antibody levels after infection display a bi-or even triphasic decay, with slowing of decay 4-6 months after infection as long-lived plasma cells and B-memory cells arise [13, 17, 25, 52] . While we could not demonstrate a better fit of a polynomial regression line between antibody levels and days after infection (corresponding to a bi or triphasic antibody decay), this might be attributable to the relatively small number of patients in our study.

Decay of antibody levels led to an estimated median time to seronegativity of anti-S of more than two years, compared to less than one year for anti-N despite a similar half-life. Using the Abbott assay, this is attributable to a higher peak antibody level of anti-S compared to anti-N, compared to their respective cut-off values. Knowlegde of the IgG anti-N kinetics is valuable in determining prior infection status in vaccinated individuals. Anti-S antibodies cannot be used for this purpose as these are induced by the vaccines themselves. As assays detecting total Ig anti-N (such as the Roche Elecsys) remain positive for a longer period, these could be more usefull for serosurveillance purposes [19, 27, 28] .

The presence of detectable anti-S antibodies translates into residual immunity, as multiple studies have shown protection from reinfection in COVID-19 convalescent individuals for up to a year after primary infection [39] [40] [41] [42] . For estimation of protective immunity on an individual level, quantitative IgG anti-S assays (such as the one from Abbott) might be more usefull than total Ig assays given the good correlation of IgG anti-S levels with neutralizing antibody titers and the correlation of neutralizing antibody titers with protection [44, 53] . Neutralizing antibody levels also seem to decline exponentially over time in most individuals, similar to the kinetics of quantitative IgG anti-S levels [28, 54] .

There is not yet a defined antibody "threshold" which identifies individuals with (in)adequate against infection and disease. It seems that a lower level of (neutralizing) antibodies is required for protection against severe disease compared than to protect against mild disease or asymptomatic infection [53] . It should be noted that protection is also dependent on other immunological mechanisms such as memory T-cells and B-cells capable of a potent secondary immune response on reexposure [8, 13, 55] . Variants of concern further complicate the relation between anti-S antibody levels and protection, as mutations in the spike protein can confer (partial) immune evasion and therefore require higher antibody levels for protection [49, 53] . There are also a few limitations to our study. First, we did not measure neutralizing antibodies which provide more direct correlation with protective immunity. We also did not asses other components of adaptive immunity such as memory B and Tcells. While IgG anti-S and anti-N antibody levels continued to decrease up to one year post positive PCR, we cannot rule out that antibodies might reach a plateau in some patients after more than 1 year. Finally, there was a difference is sex ratio for the non-severe and severe COVID-19 patients with more severe disease in men.

While this difference is in line with other studies, it might (slightly) influence antibody kinetics [56, 57] . Estimated median time to seronegativity was more than 2 years for anti-S compared to less than 1 year for anti-N despite similar half-lives, due to the higher peak antibody level/cut-off ratio for anti-S compared to anti-N.

Author Statements PV conceived the study. JVE, MO and SVDD conducted the experiments. PV and JVE analyzed the data and drafted the manuscript. All authors critically reviewed the manuscript.

The research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Conflict of interest Dr. Vermeersch reports personal fees from Roche, outside the submitted work. Dr. Lagrou reports personal fees and non-financial support from Pfizer, personal fees and non-financial support from MSD, personal fees from SMB Laboratoires, personal fees from Gilead, and personal fees from FUJIFILM Wako, outside the submitted work. The other authors state no conflicts of interests. 

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Persistence of SARS-CoV-2 specific B-and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection

Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study

Immunological memory to SARS-CoV-2 assessed for greater than six months after infection

Evolution of antibody immunity to SARS-CoV-2

Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients

Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs

Adaptive immunity to SARS-CoV-2 and COVID-19

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARSassociated coronavirus

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19

Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study

Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection

Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients

Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents

SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline

Estimated half-life of SARS-CoV-2 anti-spike antibodies more than double the half-life of antinucleocapsid antibodies in healthcare workers

The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors

Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Persistence of anti-sars-cov-2 antibodies depends on the analytical kit: A report for up to 10 months after infection

SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance

Long-lasting immune response to a mild course of PCR-confirmed SARS-CoV-2 infection: A cohort study

Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance

Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation

A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies

Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection

The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery

Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Protective immunity after recovery from SARS-CoV-2 infection

SARS-CoV-2 re-infection risk in Austria

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Waning Immunity after the BNT162b2 Vaccine in Israel

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Neutralizing antibody titres in SARS-CoV-2 infections

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in healthcare workers 2021

Author contributions PV conceived the study. JVE, MO and SVDD conducted the experiments. PV and JVE analyzed the data and drafted the manuscript